Reflects our one-for-seven reverse share split that became effective on March 15, 2024. See Note 8a to the condensed consolidated financial statements. Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets. Less than 10%. Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of September 30, 2024, 534,300 warrants were exercised for a total consideration of $4,675,125.During the nine months ended September 30, 2024, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of September 30, 2024, 32,880 warrants were exercised for a total consideration of $359,625.During the nine months ended September 30, 2024, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of September 30, 2024, 288,634 warrants were exercised for a total consideration of $3,556,976. During the nine months that ended September 30, 2024, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of September 30, 2024, 514,010 warrants were exercised for a total consideration of $4,821,416. During the nine months that ended September 30, 2024, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of September 30, 2024, 32,283 warrants were exercised for a total consideration of $405,003. During the nine months that ended September 30, 2024, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering. Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2024. Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. Reflects our one-for-seven reverse share split that became effective on March 15, 2024. See Note 8a to the condensed consolidated financial statements Balance presented net of unrecognized revenues that were not yet collected. During the nine months ended September 30, 2024, $1.6 million of the December 31, 2023 deferred revenues balance was recognized as revenues. 0001607962 false--12-31 Q3 00-0000000 0001607962 2024-01-01 2024-09-30 0001607962 2024-09-30 0001607962 lfwd:LlAndLgMember 2024-01-01 2024-09-30 0001607962 lfwd:LlAndLgMember 2024-09-30 0001607962 lfwd:IiaMember 2024-01-01 2024-09-30 0001607962 lfwd:IiaMember 2024-07-01 2024-09-30 0001607962 lfwd:IiaMember us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001607962 lfwd:IiaMember us-gaap:ConvertiblePreferredStockMember 2024-09-30 0001607962 us-gaap:IPOMember 2024-01-01 2024-09-30 0001607962 2024-07-01 2024-09-30 0001607962 2023-07-01 2023-09-30 0001607962 2023-01-01 2023-09-30 0001607962 lfwd:IiaMember 2024-09-30 0001607962 us-gaap:TrademarksMember 2024-01-01 2024-09-30 0001607962 us-gaap:TrademarksMember 2024-09-30 0001607962 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-01-01 2024-09-30 0001607962 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0001607962 lfwd:CustomerRelationshipWarrantyMember 2024-01-01 2024-09-30 0001607962 lfwd:CustomerRelationshipWarrantyMember 2024-09-30 0001607962 lfwd:CustomerRelationshipRentalMember 2024-01-01 2024-09-30 0001607962 lfwd:CustomerRelationshipRentalMember 2024-09-30 0001607962 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-09-30 0001607962 us-gaap:CustomerRelationshipsMember 2024-09-30 0001607962 lfwd:BacklogMember 2024-01-01 2024-09-30 0001607962 lfwd:BacklogMember 2024-09-30 0001607962 lfwd:AltergIncMember 2024-01-01 2024-09-30 0001607962 2023-12-31 0001607962 2022-12-31 0001607962 2023-09-30 0001607962 country:US 2023-01-01 2023-09-30 0001607962 country:US 2024-01-01 2024-09-30 0001607962 srt:EuropeMember 2023-01-01 2023-09-30 0001607962 srt:EuropeMember 2024-01-01 2024-09-30 0001607962 srt:AsiaPacificMember 2023-01-01 2023-09-30 0001607962 srt:AsiaPacificMember 2024-01-01 2024-09-30 0001607962 lfwd:RestOfWorldMember 2023-01-01 2023-09-30 0001607962 lfwd:RestOfWorldMember 2024-01-01 2024-09-30 0001607962 country:IL 2023-12-31 0001607962 country:IL 2024-09-30 0001607962 country:US 2023-12-31 0001607962 country:US 2024-09-30 0001607962 country:DE 2023-12-31 0001607962 country:DE 2024-09-30 0001607962 lfwd:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001607962 lfwd:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001607962 lfwd:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001607962 lfwd:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001607962 country:US 2024-07-01 2024-09-30 0001607962 country:US 2023-07-01 2023-09-30 0001607962 srt:EuropeMember 2024-07-01 2024-09-30 0001607962 srt:EuropeMember 2023-07-01 2023-09-30 0001607962 srt:AsiaPacificMember 2024-07-01 2024-09-30 0001607962 srt:AsiaPacificMember 2023-07-01 2023-09-30 0001607962 lfwd:RestOfWorldMember 2024-07-01 2024-09-30 0001607962 lfwd:RestOfWorldMember 2023-07-01 2023-09-30 0001607962 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001607962 2023-01-01 2023-12-31 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2023-12-31 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2024-01-01 2024-09-30 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeOneMember 2024-01-01 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeOneMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeTwoMember 2024-01-01 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeTwoMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeThreeMember 2024-01-01 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeThreeMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFourMember 2024-01-01 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFourMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwelveTwoThousandNineteenMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwelveTwoThousandNineteenMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMemberOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMemberOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember 2024-01-01 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandFifteenMember 2024-09-30 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandSixteenMember 2024-09-30 0001607962 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001607962 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001607962 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001607962 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001607962 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001607962 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001607962 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001607962 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001607962 us-gaap:EmployeeStockOptionMember 2023-12-31 0001607962 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001607962 lfwd:ShareRepurchaseProgramMember 2022-06-02 0001607962 lfwd:ShareRepurchaseProgramMember 2024-09-30 0001607962 lfwd:ShareRepurchaseProgramMember 2024-01-01 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:OfferingOfOrdinarySharesInFebruary2020Member 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:OfferingOfOrdinarySharesInFebruary2020Member 2024-01-01 2024-09-30 0001607962 lfwd:PlacementAgentMember lfwd:February2020BestEffortsOfferingMember 2024-09-30 0001607962 lfwd:PlacementAgentMember lfwd:February2020BestEffortsOfferingMember 2024-01-01 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:RegisteredDirectOfferingOfOrdinarySharesJulyTwoZeroTwoZeroMember 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:RegisteredDirectOfferingOfOrdinarySharesJulyTwoZeroTwoZeroMember 2024-01-01 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:OfferingOfOrdinarySharesDecemberTwoZeroTwoZeroMember 2024-09-30 0001607962 lfwd:CertainInstitutionalPurchasersMember lfwd:OfferingOfOrdinarySharesDecemberTwoZeroTwoZeroMember 2024-01-01 2024-09-30 0001607962 lfwd:PlacementAgentMember lfwd:December2020PrivatePlacementMember 2024-09-30 0001607962 lfwd:PlacementAgentMember lfwd:December2020PrivatePlacementMember 2024-01-01 2024-09-30 0001607962 lfwd:KreosCapitalMember 2015-12-31 0001607962 lfwd:KreosCapitalVMember 2015-01-01 2015-12-31 0001607962 lfwd:KreosCapitalVMember 2024-01-01 2024-09-30 0001607962 lfwd:KreosCapitalMember 2016-12-28 0001607962 2024-03-01 2024-03-15 0001607962 srt:MinimumMember 2024-03-01 2024-03-15 0001607962 srt:MaximumMember 2024-03-01 2024-03-15 0001607962 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-09-30 0001607962 lfwd:ShareRepurchaseProgramMember 2022-07-21 0001607962 lfwd:ShareRepurchaseProgramMember 2022-12-22 0001607962 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001607962 us-gaap:RetainedEarningsMember 2023-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001607962 us-gaap:CommonStockMember 2023-09-30 0001607962 2024-06-30 0001607962 us-gaap:RetainedEarningsMember 2024-06-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001607962 us-gaap:CommonStockMember 2024-06-30 0001607962 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001607962 us-gaap:RetainedEarningsMember 2024-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001607962 us-gaap:CommonStockMember 2024-09-30 0001607962 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001607962 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001607962 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2024-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2024-06-30 0001607962 us-gaap:TreasuryStockCommonMember 2023-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001607962 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001607962 2023-06-30 0001607962 us-gaap:RetainedEarningsMember 2023-06-30 0001607962 us-gaap:TreasuryStockCommonMember 2023-06-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001607962 us-gaap:CommonStockMember 2023-06-30 0001607962 us-gaap:RetainedEarningsMember 2022-12-31 0001607962 us-gaap:TreasuryStockCommonMember 2022-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001607962 us-gaap:CommonStockMember 2022-12-31 0001607962 us-gaap:RetainedEarningsMember 2023-12-31 0001607962 us-gaap:TreasuryStockCommonMember 2023-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001607962 us-gaap:CommonStockMember 2023-12-31 0001607962 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001607962 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001607962 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001607962 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001607962 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001607962 us-gaap:ProductMember 2023-01-01 2023-09-30 0001607962 us-gaap:ProductMember 2024-01-01 2024-09-30 0001607962 lfwd:ServiceAndWarrantyMember 2023-01-01 2023-09-30 0001607962 lfwd:ServiceAndWarrantyMember 2024-01-01 2024-09-30 0001607962 lfwd:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-09-30 0001607962 lfwd:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:RentalMember 2024-01-01 2024-09-30 0001607962 lfwd:RentalMember 2023-01-01 2023-09-30 0001607962 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001607962 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001607962 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001607962 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001607962 us-gaap:FairValueInputsLevel3Member lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001607962 us-gaap:FairValueInputsLevel3Member lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001607962 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001607962 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001607962 lfwd:EarnoutMember 2023-12-31 0001607962 lfwd:EarnoutMember 2024-09-30 0001607962 lfwd:EarnoutMember 2024-01-01 2024-09-30 0001607962 us-gaap:ProductMember 2023-07-01 2023-09-30 0001607962 us-gaap:ProductMember 2024-07-01 2024-09-30 0001607962 lfwd:RentalMember 2023-07-01 2023-09-30 0001607962 lfwd:RentalMember 2024-07-01 2024-09-30 0001607962 lfwd:ServiceAndWarrantyMember 2023-07-01 2023-09-30 0001607962 lfwd:ServiceAndWarrantyMember 2024-07-01 2024-09-30 0001607962 lfwd:AltergIncMember 2023-08-08 0001607962 lfwd:AltergIncMember 2023-08-01 2023-08-08 0001607962 lfwd:CustomerRelationshipDistributionMember 2024-09-30 0001607962 us-gaap:OrderOrProductionBacklogMember 2024-09-30 0001607962 lfwd:CustomerRelationshipDistributionMember 2024-01-01 2024-09-30 0001607962 us-gaap:OrderOrProductionBacklogMember 2024-01-01 2024-09-30 0001607962 2023-08-01 2023-08-08 0001607962 2024-11-07 iso4217:ILS xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure lfwd:segment xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024 or

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 001-36612
Lifeward Ltd.
(Exact name of registrant as specified in charter)

Israel |  | Not applicable
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
200 Donald Lynch Blvd. Marlborough, MA |  | 01752
(Address of principal executive offices) |  | (Zip Code)

+508.251.1154
Registrant's telephone number, including area code
Rewalk Robotics Ltd.
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act

Title of each class | Trading Symbol | Name of each exchange on which registered
Ordinary shares, par value NIS 1.75 | LFWD | Nasdaq Capital Market

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☒ | Smaller reporting company ☒
| Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of November 7, 2024, the registrant had outstanding 8,808,143 ordinary shares, par value NIS 1.75 per share.

LIFEWARD LTD. FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 TABLE OF CONTENTS
|  | Page No.
GENERAL AND WHERE YOU CAN FIND MORE INFORMATION | 2
PART I | FINANCIAL INFORMATION | 3
ITEM 1. | FINANCIAL STATEMENTS | 3
| CONDENSED CONSOLIDATED BALANCE SHEETS – SEPTEMBER 30, 2024 (unaudited) AND DECEMBER 31, 2023 | 3
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (unaudited) | 5
| CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY – SEPTEMBER 30, 2024 AND 2023 (unaudited) | 6
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (unaudited) | 7
| NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) | 8
ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 26
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 35
ITEM 4. | CONTROLS AND PROCEDURES | 35
PART II | OTHER INFORMATION | 36
ITEM 1. | LEGAL PROCEEDINGS | 36
ITEM 1A. | RISK FACTORS | 36
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 37
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES | 37
ITEM 4. | MINE SAFETY DISCLOSURES | 37
ITEM 5. | OTHER INFORMATION | 37
ITEM 6. | EXHIBITS | 38
SIGNATURES | 39

1

Introduction and Where You Can Find Other Information
As used in this quarterly report on Form 10-Q (this “quarterly report”), the terms “Lifeward,” the “Company,” “LL,” “we,” “us” and “our” refer to Lifeward Ltd. and its subsidiaries, unless the context clearly indicates otherwise. Our website is www.golifeward.com. Information contained in, or that can be accessed through, our website does not constitute a part of this quarterly report and is not incorporated by reference herein. We have included our website address in this quarterly report solely for informational purposes. Information that we furnish to or file with the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are available for download, free of charge, on our website as soon as reasonably practicable after such materials are filed with or furnished to the SEC. Our SEC filings, including exhibits filed or furnished therewith, are also available on the SEC’s website at http://www.sec.gov.
Special Note Regarding Forward-Looking Statements
In addition to historical information, this quarterly report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward- looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements may include projections regarding our future performance and, in some cases, can be identified by words like “anticipate,” “assume,” “believe,” “could,” “seek,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms. These statements may be found in the section of this quarterly report titled “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this quarterly report. These statements include, but are not limited to, statements regarding:

• | our expectations regarding future growth, including our ability to increase sales in our existing geographic markets and expand to new markets;

• | our ability to maintain and grow our reputation and the market acceptance of our products;

• | our ability to achieve reimbursement from third-party payors or advance Centers for Medicare & Medicaid Services (“CMS”) coverage for our products, including our ability to successfully submit and gain approval of cases for Medicare coverage through Medicare Administrative Contractors (“MACs”);

• | our ability to continue to successfully integrate the operations of AlterG, Inc. into our organization, and realize the anticipated benefits therefrom;

• | our ability to have sufficient funds to meet certain future capital requirements, which could impair our efforts to develop and commercialize existing and new products;

• | our ability to be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and our ability to handle any business disruptions that may occur in connection with streamlining operations;

• | our ability to navigate any difficulties associated with moving production of our AlterG Anti-Gravity Systems to a contract manufacturer;

• | our ability to leverage our sales, marketing and training infrastructure;

• | our ability to grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business;

• | our expectations as to our clinical research program and clinical results;

• | our ability to obtain certain components of our products from third-party suppliers and our continued access to our product manufacturers;

• | our ability to improve our products and develop new products;

• | our compliance with medical device reporting regulations to report adverse events involving our products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on our ability to market and sell our products;

• | our ability to gain and maintain regulatory approvals and to comply with any post-marketing requests;

• | the risk of a cybersecurity attack or incident relating to our information technology systems significantly disrupting our business operations;

• | our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

• | the impact of substantial sales of our shares by certain shareholders on the market price of our ordinary shares;

• | our ability to use effectively the proceeds of our offerings of securities, if any;

• | our ability to manage challenges and expenses associated with activist shareholder activities, including litigation;

• | the impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company;

• | market and other conditions, including the extent to which inflation or global instability may disrupt our business operations or our financial condition or the financial condition of our customers and suppliers, including the ongoing war in the Middle East and the increasing tensions between China and Taiwan; and

• | other factors discussed in the “Risk Factors” section of our 2023 annual report on Form 10-K and in our subsequent reports filed with the SEC.

The preceding list is not intended to be an exhaustive list of all forward-looking statements contained in this quarterly report. The statements are based on our beliefs, assumptions, and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance, or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the statements. In particular, you should consider the risks provided under “Part I, Item 1A. Risk Factors” of our 2023 annual report on Form 10-K, and in other reports subsequently filed by us with, or furnished to, the SEC.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.
Any forward-looking statement in this quarterly report speaks only as of the date hereof. Except as required by law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future developments or otherwise.
2

PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS LIFEWARD LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (unaudited) |  |  |  |
ASSETS |  |  |  |  |  |
CURRENT ASSETS |  |  |  |  |  |
Cash and cash equivalents |  | $ | 10,653 |  |  | $ | 28,083 |
Trade receivables, net of credit losses of $193 and $328, respectively |  |  | 5,843 |  |  |  | 3,120 |
Prepaid expenses and other current assets |  |  | 1,818 |  |  |  | 2,366 |
Inventories |  |  | 7,300 |  |  |  | 5,653 |
Total current assets |  |  | 25,614 |  |  |  | 39,222 |
LONG-TERM ASSETS |  |  |  |  |  |  |  |
Restricted cash and other long-term assets |  |  | 436 |  |  |  | 784 |
Operating lease right-of-use assets |  |  | 945 |  |  |  | 1,861 |
Property and equipment, net |  |  | 1,217 |  |  |  | 1,262 |
Intangible assets |  |  | 10,020 |  |  |  | 12,525 |
Goodwill |  |  | 7,538 |  |  |  | 7,538 |
Total long-term assets |  |  | 20,156 |  |  |  | 23,970 |
Total assets |  | $ | 45,770 |  |  | $ | 63,192 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

LIFEWARD LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
|  | (unaudited) |  |  |  |
LIABILITIES AND SHAREHOLDERS’ EQUITY |  |  |  |  |  |
CURRENT LIABILITIES |  |  |  |  |  |
Trade payables |  | $ | 4,992 |  |  | $ | 5,069 |
Employees and payroll accruals |  |  | 1,482 |  |  |  | 2,034 |
Deferred revenues |  |  | 1,358 |  |  |  | 1,504 |
Current maturities of operating leases liability |  |  | 936 |  |  |  | 1,296 |
Earnout liability |  |  | - |  |  |  | 576 |
Other current liabilities |  |  | 889 |  |  |  | 1,316 |
Total current liabilities |  |  | 9,657 |  |  |  | 11,795 |
LONG-TERM LIABILITIES |  |  |  |  |  |  |  |
Earnout liability |  |  | 792 |  |  |  | 2,716 |
Deferred revenues |  |  | 1,301 |  |  |  | 1,506 |
Non-current operating leases liability |  |  | 45 |  |  |  | 607 |
Other long-term liabilities |  |  | 82 |  |  |  | 58 |
Total long-term liabilities |  |  | 2,220 |  |  |  | 4,887 |
Total liabilities |  |  | 11,877 |  |  |  | 16,682 |
COMMITMENTS AND CONTINGENT LIABILITIES |  |  |  |  |  |  |  |
Shareholders’ equity: |  |  |  |  |  |  |  |
Share capital |  |  |  |  |  |  |  |
Ordinary share of NIS 1.75 par value-Authorized: 25,000,000 shares at September 30, 2024 and December 31, 2023; Issued: 9,380,291 and 9,161,798 shares at September 30, 2024 and December 31, 2023, respectively; Outstanding: 8,805,633 and 8,587,140 shares as of September 30, 2024 and December 31, 2023 respectively (1) |  |  | 4,589 |  |  |  | 4,487 |
Additional paid-in capital |  |  | 282,054 |  |  |  | 281,109 |
Treasury Shares at cost, 574,658 ordinary shares at September 30, 2024 and December 31, 2023 (1) |  |  | (3,203 | ) |  |  | (3,203 | )
Accumulated deficit |  |  | (249,547 | ) |  |  | (235,883 | )
Total shareholders’ equity |  |  | 33,893 |  |  |  | 46,510 |
Total liabilities and shareholders’ equity |  | $ | 45,770 |  |  | $ | 63,192 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
(1) Reflects our one-for-seven reverse share split that became effective on March 15, 2024. See Note 8a to the condensed consolidated financial statements.
4

LIFEWARD LTD. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share data)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues |  | $ | 6,128 |  |  | $ | 4,403 |  |  | $ | 18,118 |  |  | $ | 6,970 |
Cost of revenues |  |  | 3,908 |  |  |  | 3,540 |  |  |  | 11,746 |  |  |  | 4,960 |
Gross profit |  |  | 2,220 |  |  |  | 863 |  |  |  | 6,372 |  |  |  | 2,010 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development, net |  |  | 998 |  |  |  | 1,262 |  |  |  | 3,494 |  |  |  | 2,830 |
Sales and marketing |  |  | 4,156 |  |  |  | 4,088 |  |  |  | 13,573 |  |  |  | 9,076 |
General and administrative |  |  | 240 |  |  |  | 3,455 |  |  |  | 3,424 |  |  |  | 7,579 |
Total operating expenses |  |  | 5,394 |  |  |  | 8,805 |  |  |  | 20,491 |  |  |  | 19,485 |
Operating loss |  |  | (3,174 | ) |  |  | (7,942 | ) |  |  | (14,119 | ) |  |  | (17,475 | )
Financial income, net |  |  | 119 |  |  |  | 411 |  |  |  | 495 |  |  |  | 1,047 |
Loss before income taxes |  |  | (3,055 | ) |  |  | (7,531 | ) |  |  | (13,624 | ) |  |  | (16,428 | )
Taxes on income |  |  | 29 |  |  |  | - |  |  |  | 40 |  |  |  | 66 |
Net loss |  | $ | (3,084 | ) |  | $ | (7,531 | ) |  | $ | (13,664 | ) |  | $ | (16,494 | )
Net loss per ordinary share, basic and diluted |  | $ | (0.35 | ) |  | $ | (0.88 | ) |  | $ | (1.58 | ) |  | $ | (1.94 | )
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (1) |  |  | 8,756,882 |  |  |  | 8,542,630 |  |  |  | 8,652,085 |  |  |  | 8,501,397 |

(1) Reflects our one-for-seven reverse share split that became effective on March 15, 2024. See Note 8a to the condensed consolidated financial statements.
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

LIFEWARD LTD. AND SUBSIDIARIES
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(Unaudited)
(In thousands, except share data)

|  | Ordinary Shares |  |  | Additional paid-in |  |  | Treasury |  |  | Accumulated |  |  | Total shareholders’ |
|  | Number (1) |  |  | Amount |  |  | capital |  |  | Shares |  |  | deficit |  |  | equity |
Balance as of June 30, 2023 |  |  | 8,478,003 |  |  | $ | 4,435 |  |  | $ | 280,455 |  |  | $ | (3,203 | ) |  | $ | (222,713 | ) |  | $ | 58,974 |
Share-based compensation to employees and non-employees |  |  | - |  |  |  | - |  |  |  | 333 |  |  |  | - |  |  |  | - |  |  |  | 333 |
Issuance of ordinary shares upon vesting of employees and non-employees RSUs |  |  | 96,911 |  |  |  | 46 |  |  |  | (46 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,531 | ) |  |  | (7,531 | )
Balance as of September 30, 2023 |  |  | 8,574,914 |  |  | $ | 4,481 |  |  | $ | 280,742 |  |  | $ | (3,203 | ) |  | $ | (230,244 | ) |  | $ | 51,776 |
Balance as of June 30, 2024 |  |  | 8,630,902 |  |  | $ | 4,508 |  |  | $ | 281,845 |  |  | $ | (3,203 | ) |  | $ | (246,463 | ) |  | $ | 36,687 |
Share-based compensation to employees and non-employees |  |  | - |  |  |  | - |  |  |  | 290 |  |  |  | - |  |  |  | - |  |  |  | 290 |
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees |  |  | 174,731 |  |  |  | 81 |  |  |  | (81 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (3,084 | ) |  |  | (3,084 | )
Balance as of September 30, 2024 |  |  | 8,805,633 |  |  | $ | 4,589 |  |  | $ | 282,054 |  |  | $ | (3,203 | ) |  | $ | (249,547 | ) |  | $ | 33,893 |

|  | Ordinary Shares |  |  | Additional paid-in |  |  | Treasury |  |  | Accumulated |  |  | Total shareholders’ |
|  | Number (1) |  |  | Amount |  |  | capital |  |  | Shares |  |  | deficit |  |  | equity |
Balance as of December 31, 2022 |  |  | 8,584,313 |  |  | $ | 4,489 |  |  | $ | 279,857 |  |  | $ | (2,431 | ) |  | $ | (213,750 | ) |  | $ | 68,165 |
Share-based compensation to employees and non-employees |  |  | - |  |  |  | - |  |  |  | 955 |  |  |  | - |  |  |  | - |  |  |  | 955 |
Issuance of ordinary shares upon vesting of employees and non-employees RSUs |  |  | 146,230 |  |  |  | 70 |  |  |  | (70 | ) |  |  | - |  |  |  | - |  |  |  | - |
Treasury shares at cost |  |  | (155,629 | ) |  |  | (78 | ) |  |  |  |  |  |  | (772 | ) |  |  |  |  |  |  | (850 | )
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (16,494 | ) |  |  | (16,494 | )
Balance as of September 30, 2023 |  |  | 8,574,914 |  |  | $ | 4,481 |  |  | $ | 280,742 |  |  | $ | (3,203 | ) |  | $ | (230,244 | ) |  | $ | 51,776 |
Balance as of December 31, 2023 |  |  | 8,587,140 |  |  | $ | 4,487 |  |  | $ | 281,109 |  |  | $ | (3,203 | ) |  | $ | (235,883 | ) |  | $ | 46,510 |
Share-based compensation to employees and non-employees |  |  | - |  |  |  | - |  |  |  | 1,047 |  |  |  | - |  |  |  | - |  |  |  | 1,047 |
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees |  |  | 218,493 |  |  |  | 102 |  |  |  | (102 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (13,664 | ) |  |  | (13,664 | )
Balance as of September 30, 2024 |  |  | 8,805,633 |  |  | $ | 4,589 |  |  | $ | 282,054 |  |  | $ | (3,203 | ) |  | $ | (249,547 | ) |  | $ | 33,893 |

(1) Reflects our one-for-seven reverse share split that became effective on March 15, 2024. See Note 8a to the condensed consolidated financial statements
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

LIFEWARD LTD. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Cash flows used in operating activities: |  |  |  |  |  |
Net loss |  | $ | (13,664 | ) |  | $ | (16,494 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation |  |  | 370 |  |  |  | 134 |
Amortization of intangible assets |  |  | 2,505 |  |  |  | 764 |
Share-based compensation |  |  | 1,047 |  |  |  | 955 |
Remeasurement of earnout liability |  |  | (2,500 | ) |  |  | 40 |
Interest income |  |  | (2 | ) |  |  | (13 | )
Exchange rate fluctuations |  |  | 29 |  |  |  | 24 |
Changes in assets and liabilities: |  |  |  |  |  |  |  |
Trade receivables, net |  |  | (2,723 | ) |  |  | (720 | )
Prepaid expenses, operating lease right-of-use assets and other assets |  |  | 2,017 |  |  |  | (849 | )
Inventories |  |  | (2,523 | ) |  |  | (480 | )
Trade payables |  |  | (77 | ) |  |  | 1,895 |
Employees and payroll accruals |  |  | (552 | ) |  |  | (347 | )
Deferred revenues |  |  | (351 | ) |  |  | (23 | )
Operating lease liabilities and other liabilities |  |  | (1,325 | ) |  |  | (1,069 | )
Net cash used in operating activities |  | $ | (17,749 | ) |  | $ | (16,183 | )
Cash flows used investing activities: |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | - |  |  |  | (2 | )
Acquisition of a business, net of cash acquired |  |  | - |  |  |  | (18,068 | )
Net cash used in investing activities |  | $ | - |  |  | $ | (18,070 | )
Cash flows used in financing activities: |  |  |  |  |  |  |  |
Purchase of treasury shares |  |  | - |  |  |  | (992 | )
Net cash used in financing activities |  | $ | - |  |  | $ | (992 | )
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash |  |  | (29 | ) |  |  | (24 | )
Decrease in cash, cash equivalents, and restricted cash |  |  | (17,778 | ) |  |  | (35,269 | )
Cash, cash equivalents, and restricted cash at beginning of period |  |  | 28,792 |  |  |  | 68,555 |
Cash, cash equivalents, and restricted cash at end of period |  | $ | 11,014 |  |  | $ | 33,286 |
Supplemental disclosures of non-cash flow information |  |  |  |  |  |  |  |
Classification of inventory to property and equipment, net |  | $ | 325 |  |  | $ | 194 |
ROU assets obtained from new lease liabilities |  | $ | - |  |  | $ | 513 |
Supplemental cash flow information: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 10,653 |  |  | $ | 32,590 |
Restricted cash included in other long-term assets |  |  | 361 |  |  |  | 696 |
Total Cash, cash equivalents, and restricted cash |  | $ | 11,014 |  |  | $ | 33,286 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
7

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1: GENERAL

| a. | L ifeward Ltd. (“LL,” and together with its subsidiaries, the “Company”) was originally incorporated under the laws of the State of Israel on June 20, 2001, and commenced operations on the same date under the name Argo Medical Technologies Ltd. This name was later changed to ReWalk Robotics Ltd. on June 18, 2014. On January 29, 2024, the Company announced that it had rebranded as Lifeward, with each subsidiary of LL renamed to reflect the new corporate identity. The Company officially changed its name to Lifeward Ltd. on September 10, 2024.

| b. | LL has three wholly owned (directly and indirectly) subsidiaries: (i) Lifeward Inc. (“LI”) originally incorporated under the laws of Delaware on February 15, 2012 under the name of ReWalk Robotics, Inc., (ii) Lifeward GMBH (“LG”) originally incorporated under the laws of Germany on January 14, 2013 under the name of ReWalk Robotics GMBH, and (iii) Lifeward CA, Inc. ( “LCAI”) originally incorporated in Delaware on October 21, 2004 under the name of Gravus, Inc., which was later changed to AlterG, Inc. on June 30, 2005.

| c. | The Company is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. The Company’s initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (collectively, the “SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use the Company’s patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community. The Company has sought to expand its product offerings beyond the SCI Products through internal development and distribution agreements. The Company has developed its ReStore Exo-Suit device (the “ReStore”), which it began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disabilities due to stroke. During the second quarter of 2020, the Company signed an agreement to distribute product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. We refer to the MyoCycle devices as our “Distributed Product.” On August 11, 2023, pursuant to an Agreement and Plan of Merger among LI, AlterG, Inc., Atlas Merger Sub, Inc., a wholly owned subsidiary of AlterG, Inc. (“Merger Sub”), and Shareholder Representative Services LLC, dated August 8, 2023, LI acquired AlterG, Inc. and AlterG, Inc. became a wholly owned subsidiary of the Company. With the rebranding of the Company, AlterG, Inc. was renamed as LCAI. For accounting purposes, LI was considered the acquirer and AlterG, Inc. was considered the acquiree. The acquisition was accounted for using the acquisition method of accounting. See Note 5 for additional information. The Company made its first acquisition to supplement its internal growth when it acquired AlterG, Inc., a leading provider of anti-gravity systems for use in physical and neurological rehabilitation. The Company paid a cash purchase price of approximately $19 million at closing and additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year revenue growth over the two years following the closing. The AlterG anti-gravity systems use patented, NASA-derived Differential Air Pressure (“DAP”) technology to reduce the effects of gravity and allow people to rehabilitate with finely calibrated support and reduced pain. The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with neurological injury and disability.

8

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

|  | The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in the United States, through a combination (depending on the product line) of direct sales and distributors in Germany, Canada, and Australia, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships.

| d. | As of September 30, 2024, the Company incurred a consolidated net loss of $13.7 million and has an accumulated deficit in the total amount of $249.5 million. The Company’s cash and cash equivalents as of September 30, 2024 totaled $10.7 million and the Company’s negative operating cash flow for the nine months ended September 30, 2024 was $17.7 million. The Company believes it has sufficient funds to support its operations for more than 12 months following the issuance date of its unaudited condensed consolidated financial statements for the nine months ended September 30, 2024.

| e. | The Company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the successful development and commercialization of its products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenues adequate to support its cost structure. If the Company does not achieve a level of revenues adequate to support its cost structure, it will implement cost reduction measures. These plans may include restructuring efforts and additional cost reductions if needed. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.

NOTE 2: BASIS OF PRESANTATION AND SUMMARY OF ESTIMATES
Basis of Presentation and Consolidation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.
These unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the 2023 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023 (the “2023 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the consolidated financial statements for the fiscal year ended December 31, 2023, included in the 2023 Form 10-K, unless otherwise stated.
Use of Estimates
The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, assets acquired and liabilities assumed in business combinations, revenue recognition, deferred revenue, fair values of share-based awards, contingent liabilities, provision for warranty and allowance for credit losses. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

9

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 3: SIGNIFICANT ACCOUNTING POLICIES

| a. | Business Combinations The Company accounts for business combinations in accordance with ASC 805, “Business Combinations”. For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged. The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment. Acquisition-related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.

| b. | Goodwill and Other Intangibles For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill. The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets. Goodwill is not amortized and is tested for impairment at least annually. The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.

10

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The Company determined no impairment existed for goodwill for the three and nine months ended September 30, 2024.
The Company evaluates the recoverability of long-lived assets, including property and equipment and intangible assets subject to amortization for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. Such events and changes may include significant changes in performance relative to expected operating results, significant changes in asset use, significant negative industry or economic trends, and changes in the Company’s business strategy. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If such review indicates that the carrying amount of long-lived assets is not recoverable, the carrying amount of such assets is reduced to fair value. There were no impairment charges to long-lived assets during the periods presented.

| c. | Fair Value Measurements

Cash and cash equivalents, restricted cash, prepaid expenses and other assets, trade payables and accrued expenses and other liabilities, are stated at their carrying value which approximates their fair value due to the short time to the expected receipt or payment.
The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands):

|  |  |  | Fair value measurements as of |
Description |  | Fair Value Hierarchy |  | September 30, 2024 |  |  | December 31, 2023 |
Financial assets: |  |  |  |  |  |  |  |
Money market funds included in cash and cash equivalent |  | Level 1 |  | $ | 2,665 |  |  | $ | 2,550 |
Treasury bills included in cash and cash equivalent |  | Level 1 |  |  | 1,313 |  |  |  | 2,525 |
Total Assets Measured at Fair Value |  |  |  | $ | 3,978 |  |  | $ | 5,075 |
Financial Liabilities: |  |  |  |  |  |  |  |  |  |
Earnout |  | Level 3 |  | $ | 792 |  |  | $ | 3,292 |
Total liabilities measured at fair value |  |  |  | $ | 792 |  |  | $ | 3,292 |

The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.
The estimated fair value of the earnout is determined using Level 3 inputs. Inherent in a Monte Carlo simulation analysis are assumptions related to projected revenues, expected term, volatility, annual revenue yield and interest rate. The Company estimates the volatility of its common share based on historical volatility of select peer companies. The interest rate is based on the U.S. Technology B bond yield.

11

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table summarizes the earnout liability activity as of September 30, 2024 (in thousands):

|  | Earnout |
Balance December 31, 2023 |  | $ | 3,292 |
Change in fair value |  |  | (2,500 | )
Balance September 30, 2024 |  | $ | 792 |

| d. | Revenue Recognition

The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centers, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.
Disaggregation of Revenues (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Product |  | $ | 4,800 |  |  | $ | 3,632 |  |  | $ | 13,667 |  |  | $ | 5,563 |
Rental |  |  | 1,008 |  |  |  | 303 |  |  |  | 2,776 |  |  |  | 685 |
Service and warranty |  |  | 320 |  |  |  | 468 |  |  |  | 1,675 |  |  |  | 722 |
Total Revenues |  | $ | 6,128 |  |  | $ | 4,403 |  |  | $ | 18,118 |  |  | $ | 6,970 |

Product revenue
Revenue from Products sold to rehabilitation facilities and end users is recognized at a point in time once the customer has obtained the legal title to the items purchased.
For ReWalk and ReStore systems sold to rehabilitation facilities, the Company provides an immaterial level of training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system and training only after delivery in accordance with the agreement's delivery terms to the customer and after the training has been completed.
For sales of ReWalk systems to end users, the Company does not provide training to the end user as this training is provided separately by the rehabilitation center that the end user chooses to use. Similarly, for sales of ReWalk systems to third party distributors, the Company does not provide training to the distributor because the distributor would previously have completed the ReWalk Training program. Therefore, in both cases the Company recognizes revenue upon delivery.
The Company generally does not grant a right of return for its products. In the rare circumstances when the Company provides a right of return for its products, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.
The Company offered five products: (1) ReWalk Personal, (2) ReWalk Rehabilitation, (3) ReStore, (4) MyoCycle and (5) AlterG Anti-Gravity system.

12

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ReWalk Personal and ReWalk Rehabilitation are SCI Products, which are currently designed for everyday use by paraplegic individuals at home and in their communities. SCI Products are custom fitted for each user, as well as for use by paraplegic patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReWalk Rehabilitation is a ReWalk Personal product sold with multiple sizes of our adjustable parts to allow different users the ability to train within a clinic.
With the recent establishment of a Medicare reimbursement pathway for the ReWalk product, the Company includes variable consideration in the form of implicit price concessions if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company reassesses variable consideration at each reporting period and, if necessary, these estimates are adjusted to reflect the anticipated amounts to be collected when those facts and circumstances become known.
The AlterG Anti-Gravity systems are used in physical and neurological rehabilitation and athletic training, both domestically and internationally. This transformative technology uses patented, NASA-derived DAP technology to reduce the effects of gravity and allow people to move with finely calibrated support and reduced pain.
The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment.
The Company also sells the MyoCycle, which uses Functional Electrical Stimulation (“FES”) technology, in the United States for use at home or in clinic.
Rental revenue
Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis.
The Company also offers the SCI Products in a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.
Service and warranties
The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered, which corresponds with the period in which the related expenses are incurred.
Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.
In recent years, SCI Products have included a five-year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty. With the recent establishment of a Medicare reimbursement pathway, the Company will offer its SCI Products to qualified Medicare beneficiaries with a two-year assurance type warranty only.
The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.
The Distributed Product is sold with an assurance type warranty ranging from between one year to ten years, depending on the specific product and part.
For AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.
Contract balances (in thousands):

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Trade receivable, net of credit losses (1) |  | $ | 5,843 |  |  | $ | 3,120 |
Deferred revenues (1) (2) |  | $ | 2,659 |  |  | $ | 3,010 |

| (1) | Balance presented net of unrecognized revenues that were not yet collected.

| (2) | During the nine months ended September 30, 2024, $1.6 million of the December 31, 2023 deferred revenues balance was recognized as revenues.

Deferred revenue is composed primarily of unearned revenue related to service type warranty obligations, multi-year services contracts, as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized.
The Company’s unearned performance obligations as of September 30, 2024 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $2.7 million, which will be fulfilled over one to five years.

13

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| e. | Concentrations of Credit Risks:

The below table reflects the concentration of credit risk for the Company’s current customers as of September 30, 2024, to which substantial sales were made:

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Customer A |  |  | 42 | % |  |  | - |

The allowance for credit losses is based on the Company’s assessment of the collectability of accounts. The Company regularly assessed collectability based on a combination of factors, including an assessment of the current customer’s aging balance, the nature and size of the customer, the financial condition of the customer, and future expected economic conditions. Trade receivables deemed uncollectable are charged against the allowance for credit losses when identified. As of September 30, 2024, and December 31, 2023, trade receivables are presented net of allowance for credit losses in the amount of $193 thousand and $328 thousand, respectively.

| f. | Warranty provision

For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.

|  | US Dollars in thousands |
Balance at December 31, 2023 |  | $ | 348 |
Provision |  |  | 606 |
Usage |  |  | (530 | )
Balance at September 30, 2024 |  | $ | 424 |

| g. | Basic and diluted net loss per ordinary share:

Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive.
As of September 30, 2024 and 2023, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 2,503,297 and 2,780,512, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.

14

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| h. | New Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

| i. | In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.
| ii. | In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.

NOTE 4: INVENTORIES
The components of inventories are as follows (in thousands):

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Finished products |  | $ | 4,174 |  |  | $ | 3,157 |
Raw materials |  |  | 3,126 |  |  |  | 2,496 |
|  | $ | 7,300 |  |  | $ | 5,653 |

NOTE 5: BUSINESS COMBINATION
On August 11, 2023, pursuant to an Agreement and Plan of Merger among LI, AlterG, Inc., Merger Sub, and Shareholder Representative Services LLC, LI, August 8, 2023, the Company acquired AlterG, Inc.and AlterG, Inc.became a wholly owned subsidiary of the Company. With the rebranding of the Company, AlterG, Inc. was renamed as LCAI. LCAI develops, manufactures, and markets anti-gravity systems for use in physical and neurological rehabilitation and athletic training, both in the United States and internationally. The aggregate purchase price was a total of approximately $19 million in cash, subject to working capital and other customary purchase price adjustments. Additional cash earnouts (initially estimated to be approximately $4.0 million in the aggregate) may be paid based upon a percentage of LCAI’s year-over-year future revenue growth over the next two years subject to working capital and other customary purchase price adjustments.

The total consideration transferred is as follows (in thousands): |  |  |
Cash |  | $ | 18,493 |
Earnout payments |  | $ | 3,607 |
Total consideration |  | $ | 22,100 |

Earnout payments

The Company will pay an amount of cash equal to 65% of the amount, if any, by which LCAI revenue attributable to the first 12 months period exceeds revenue target ("first earnout payment"), and an amount in cash equal to 65% of the amount, if any, by which LCAI revenue attributable to the following 12 months period exceeds the revenue from the first 12 month period ("second earnout payment"). However, the company did not meet the revenue target for the first year of the earnout, and as a result, no payment will be made for the first year. At the date of acquisition, management estimated fair value of the earnout payment based on the actual up to date performance of the acquired entity and the probability of the earn out payment occurrence to be at approximately $3.6 million. The earn-out was accounted for as a liability and will be remeasured at each reporting period through consolidated statement of operations.

15

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The Company has accounted for the LCAI acquisition as a business combination. The Company has preliminarily allocated the purchase price of approximately $22.1 million fair values, and the excess of the purchase price over the aggregate fair values is recorded as goodwill.
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date (in thousands):

Cash and cash equivalent |  | $ | 478 |
Restricted cash |  |  | 51 |
Accounts receivable |  |  | 1,773 |
Inventory |  |  | 3,330 |
Prepaid expenses and other current assets |  |  | 470 |
Right of use asset |  |  | 1,151 |
Property and equipment, net |  |  | 827 |
Other non-current assets |  |  | 30 |
Goodwill |  |  | 7,538 |
Intangible assets |  |  | 14,133 |
Accounts payable |  |  | (2,082 | )
Accrued compensation |  |  | (766 | )
Other accrued liabilities |  |  | (1,059 | )
Deferred revenue |  |  | (2,088 | )
Warranty Obligations |  |  | (535 | )
Leases Liability |  |  | (1,151 | )
Total purchase consideration |  | $ | 22,100 |

The following table presents the details of the intangible assets acquired at the date of LCAI acquisition (in thousands):

|  | Estimated Fair Value |  |  | Estimated Useful Life (Years) |
Trademark |  | $ | 795 |  |  |  | 3 |
Technology |  |  | 6,161 |  |  |  | 4 |
Customer relationship - Warranty |  |  | 201 |  |  |  | 2 |
Customer relationship - Rental |  |  | 2,102 |  |  |  | 4 |
Customer relationship - Distribution |  |  | 4,578 |  |  |  | 5 |
Backlog |  |  | 296 |  |  |  | 1 |

Under the purchase price allocation, the Company allocates the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the estimates of their fair values. The fair values for the intangible assets acquired were primarily based on significant inputs that are not observable in the market and thus represent a Level 3 measurement in the fair value hierarchy. Customer relationships, distributor relationships, backlog, trademark and developed technology were valued using the income approach, based on estimated projections of expected cash flows to be generated by the assets, discounted to the present value at discount rates commensurate with perceived risk. The discounted cash flow analyses factor in assumptions on revenue and expense growth rates including estimates of customer growth and attrition rates, distributor growth and attrition rates, technology obsolescence, and relief from royalty projections. Additionally, these discounted cash flow analyses factor in expected amounts of working capital, fixed assets, assembled workforce and cost of capital for each intangible asset.

16

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 6: GOODWILL AND OTHER INTANGIBLE ASSETS, NET
The Company has $7.5 million of goodwill related to its purchase of LCAI in the third quarter of fiscal year 2023, which has an indefinite life, and is not deductible for tax purposes.
As of September 30, 2024, the components of, and changes in, the carrying amount of intangible assets, net, were as follows (in thousands):

|  | Cost |  |  | September 30, 2024 Accumulated Amortization |  |  | Intangible Assets, Net |
Trademark |  | $ | 795 |  |  | $ | (302 | ) |  | $ | 493 |
Technology |  |  | 6,161 |  |  |  | (1,757 | ) |  |  | 4,404 |
Customer relationship - Warranty |  |  | 201 |  |  |  | (115 | ) |  |  | 86 |
Customer relationship - Rental |  |  | 2,102 |  |  |  | (600 | ) |  |  | 1,502 |
Customer relationship - Distribution |  |  | 4,578 |  |  |  | (1,043 | ) |  |  | 3,535 |
Backlog |  |  | 296 |  |  |  | (296 | ) |  | ‐ |
Total Amortized Intangible Assets |  | $ | 14,133 |  |  | $ | (4,113 | ) |  | $ | 10,020 |

The estimated amortization expense is shown below (in thousands):

Fiscal 2024 (period remaining) |  |  |  |  |  |  |  |  |  | $ | 842 |
Fiscal 2025 |  |  |  |  |  |  |  |  |  |  | 3,307 |
Fiscal 2026 |  |  |  |  |  |  |  |  |  |  | 3,143 |
Fiscal 2027 |  |  |  |  |  |  |  |  |  |  | 2,172 |
Fiscal 2028 |  |  |  |  |  |  |  |  |  |  | 556 |
Total |  |  |  |  |  |  |  |  |  | $ | 10,020 |

NOTE 7: COMMITMENTS AND CONTINGENT LIABILITIES

| a. | Purchase commitments:

The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be canceled without penalty. As of September 30, 2024, non-cancelable outstanding obligations amounted to approximately $5.9 million.

| b. | Operating lease commitment:

| (i) | The Company operates from leased facilities in Israel, the United States and Germany. These leases expire in 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (the “CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.

17

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| (ii) | LL and LG lease cars for their employees under cancelable operating lease agreements expiring at various dates between 2024 and 2026. A subset of the Company’s car leases is considered variable. The variable lease payments for such car leases are based on actual mileage incurred at the stated contractual rate. LL and LG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $28 thousand as of September 30, 2024.

The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s condensed consolidated balance sheets as of September 30, 2024 are as follows (in thousands):

2024 |  | $ | 342 |
2025 |  |  | 670 |
2026 |  |  | 12 |
Total lease payments |  |  | 1,024 |
Less: imputed interest |  |  | (43 | )
Present value of future lease payments |  |  | 981 |
Less: current maturities of operating leases |  |  | 936 |
Non-current operating leases |  | $ | 45 |
Weighted-average remaining lease term (in years) |  |  | 0.92 |
Weighted-average discount rate |  |  | 9.12 | %

Lease expense under the Company’s operating leases was $321 thousand and $269 thousand for the three months ended September 30, 2024 and 2023 respectively. For the nine months ended September 30, 2024 and 2023 the lease expense was $974 thousand and $657 thousand, respectively.

| c. | Royalties

The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”). Since the Company’s inception through September 30, 2024, the Company received funding from the IIA in the total amount of $2.8 million. Out of the $2.8 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $806 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.
As of September 30, 2024, the Company paid royalties to the IIA in the total amount of $114 thousand.
For the three and nine months ended September 30, 2024, the royalties expenses were $2 thousand. There were no royalty expenses for the three and nine months ended September 30, 2023.
As of September 30, 2024, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases:

18

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer);
(b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient.
In accordance with the License Agreement with Harvard, the Company is required to pay royalties on net sales. Refer to note 10 in our 2023 Form 10-K for details regarding the License Agreement.
LCAI earns royalties under a license agreement with a third party and is recognized as earned. Royalty payments for the three and nine months ended September 30, 2024, were $0 and $55 thousand, respectively. Royalty payments for the limited consolidation period ended September 30, 2023 were $31 thousand following the acquisition of AlterG in August 2023.

| d. | Liens:

As part of the Company’s other long-term assets and restricted cash, an amount of $361 thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.

| e. | Legal Claims:

Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. The outcome of any pending or threatened litigation and other legal matters is inherently uncertain, and it is possible that resolution of any such matters could result in losses material to the Company’s consolidated results of operations, liquidity, or financial condition. Except as otherwise disclosed herein, the Company is not currently party to any material litigation.

19

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 8: SHAREHOLDERS’ EQUITY

| a. | Reverse share split:

At the Company’s 2023 annual general meeting, the Company’s shareholders approved (i) a reverse share split within a range of 1:2 to 1:12, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) so that the maximum number of authorized ordinary shares would be 120 million. In accordance with the shareholder approval, in early March 2024 the Board of Directors of the Company approved a one-for-seven reverse share split of the Company’s ordinary shares, reducing the number of the Company’s issued and outstanding ordinary shares from approximately 60.1 million pre-split shares to approximately 8.6 million post-split shares. The Company’s ordinary shares began trading on a split-adjusted basis on March 15, 2024. Additionally, effective at the same time, the total authorized number of ordinary shares of the Company was adjusted to 25 million post-split shares, the par value per share of the ordinary shares changed to NIS 1.75 and the authorized share capital of the Company changed from NIS 30,000,000 to NIS 43,750,000. All share and per share data included in these condensed consolidated financial statements give retroactive effect to the reverse share split for all periods presented.
Upon the effectiveness of the reverse share split, every seven shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.
No fractional shares were issued in connection with the reverse share split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded down to the nearest whole number.

| b. | Share option plans:

As of September 30, 2024, no ordinary shares were reserved, as the Company’s 2014 Incentive Compensation Plan (the “2014 Plan”) was terminated on August 19, 2024, and a new plan has not yet been approved as a replacement. As of December 31, 2023, the Company had reserved 145,560 ordinary shares for issuance to the Company’s and its affiliates’ respective employees, directors, officers, and consultants pursuant to equity awards granted under the 2014 Plan.
Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Under the 2014 Plan, any option that was forfeited or canceled before expiration became available for future grants. However, as the 2014 Plan was terminated on August 19, 2024, no further options will be granted under this plan.
There were no options granted during the nine months that ended September 30, 2024, and 2023.
The fair value of RSUs granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee share options activity during the nine months ended September 30, 2024, is as follows:

|  | Number |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual life (years) |  |  | Aggregate intrinsic value (in thousands) |
Options outstanding as of December 31, 2023 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 4.39 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Forfeited |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Options outstanding as of September 30, 2024 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 3.62 |  |  | $ | - |
Options exercisable as of September 30, 2024 |  |  | 4,723 |  |  | $ | 259.73 |  |  |  | 3.62 |  |  | $ | - |

The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the nine months ended September 30, 2024 and 2023.

20

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

A summary of employees and non-employees RSUs activity during the nine months ended September 30, 2024 is as follows:

|  | Number of shares underlying outstanding RSUs |  |  | Weighted- average grant date fair value |
Unvested RSUs as of December 31, 2023 |  |  | 538,885 |  |  | $ | 6.07 |
Granted |  |  | 14,740 |  |  |  | 4.80 |
Vested |  |  | (218,493 | ) |  |  | 6.56 |
Forfeited |  |  | (3,413 | ) |  |  | 6.86 |
Unvested RSUs as of September 30, 2024 |  |  | 331,719 |  |  | $ | 5.68 |

The weighted average grant date fair value of RSUs granted during the nine months ended September 30, 2024, and 2023 was $4.80 and $4.69, respectively.
As of September 30, 2024, there were $1.7 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2014 Plan. This cost is expected to be recognized over a period of approximately 2.3 years.
The number of options and RSUs outstanding as of September 30, 2024 is set forth below, with options separated by range of exercise price.

|  |  | Weighted average remaining contractual life (years) (1) |  |  | Options outstanding and exercisable as of September 30, 2024 |  |  | Weighted average remaining contractual life (years) (1) |
Range of exercise price |  |  | Options and RSUs outstanding as of September 30, 2024 |  |  |  |  |  |  |
RSUs only |  |  |  | 331,719 |  |  |  | - |  |  |  | - |  |  |  | - |
$37.6 |  |  |  | 1,774 |  |  |  | 4.49 |  |  |  | 1,774 |  |  |  | 4.49 |
$178.5 - $236.3 |  |  |  | 1,845 |  |  |  | 3.59 |  |  |  | 1,845 |  |  |  | 3.59 |
$350 - $367.5 |  |  |  | 887 |  |  |  | 2.65 |  |  |  | 887 |  |  |  | 2.65 |
$1,277.5 - $3,634.8 |  |  |  | 217 |  |  |  | 0.63 |  |  |  | 217 |  |  |  | 0.63 |
|  |  |  | 336,442 |  |  |  | 3.62 |  |  |  | 4,723 |  |  |  | 3.62 |

| (1) | Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

| c. | Share-based awards to non-employee consultants:

As of September 30, 2024, there are no outstanding options or RSUs held by non-employee consultants.

21

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| d. | Treasury shares:

On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8.0 million of its Ordinary Shares, par value NIS
0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, the Company’s Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.
As of September 30, 2024, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 574,658 of its outstanding ordinary shares at a total cost of $3.5 million.

| e. | Warrants to purchase ordinary shares:

The following table summarizes information about warrants outstanding and exercisable that were classified as equity as of September 30, 2024:

Issuance date |  | Warrants outstanding |  |  | Exercise price per warrant |  |  | Warrants outstanding and exercisable |  | Contractual term
|  | (number) |  |  |  |  |  | (number) |  |
December 31, 2015 (1) |  |  | 681 |  |  | $ | 52.50 |  |  |  | 681 |  | See footnote (1)
December 28, 2016 (2) |  |  | 272 |  |  | $ | 52.50 |  |  |  | 272 |  | See footnote (1)
April 5, 2019 (3) |  |  | 58,350 |  |  | $ | 35.98 |  |  |  | 58,350 |  | October 7, 2024
June 12, 2019 (4) |  |  | 59,523 |  |  | $ | 42.00 |  |  |  | 59,523 |  | December 12, 2024
February 10, 2020 (5) |  |  | 4,054 |  |  | $ | 8.75 |  |  |  | 4,054 |  | February 10, 2025
February 10, 2020 (6) |  |  | 15,120 |  |  | $ | 10.94 |  |  |  | 15,120 |  | February 10, 2025
July 6, 2020 (7) |  |  | 64,099 |  |  | $ | 12.32 |  |  |  | 64,099 |  | January 2, 2026
July 6, 2020 (8) |  |  | 42,326 |  |  | $ | 15.95 |  |  |  | 42,326 |  | January 2, 2026
December 8, 2020 (9) |  |  | 83,821 |  |  | $ | 9.38 |  |  |  | 83,821 |  | June 8, 2026
December 8, 2020 (10) |  |  | 15,543 |  |  | $ | 12.55 |  |  |  | 15,543 |  | June 8, 2026
February 26, 2021 (11) |  |  | 780,095 |  |  | $ | 25.20 |  |  |  | 780,095 |  | August 26, 2026
February 26, 2021 (12) |  |  | 93,612 |  |  | $ | 32.05 |  |  |  | 93,612 |  | August 26, 2026
September 29, 2021 (13) |  |  | 1,143,821 |  |  | $ | 14.00 |  |  |  | 1,143,821 |  | March 29, 2027
September 29, 2021 (14) |  |  | 137,257 |  |  | $ | 17.81 |  |  |  | 137,257 |  | September 27, 2026
|  |  | 2,498,574 |  |  |  |  |  |  |  | 2,498,574 |  |

22

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| (1) | Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2024.

| (2) | Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.

| (3) | Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.

| (4) | Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.

| (5) | Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of September 30, 2024, 534,300 warrants were exercised for a total consideration of $4,675,125. During the nine months ended September 30, 2024, no warrants were exercised.

| (6) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of September 30, 2024, 32,880 warrants were exercised for a total consideration of $359,625. During the nine months ended September 30, 2024, no warrants were exercised.

23

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

| (7) | Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of September 30, 2024, 288,634 warrants were exercised for a total consideration of $3,556,976. During the nine months that ended September 30, 2024, no warrants were exercised.

| (8) | Represents warrants that were issued to the placement agent as compensation for his role in the Company’s July 2020 registered direct offering.

| (9) | Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of September 30, 2024, 514,010 warrants were exercised for a total consideration of $4,821,416. During the nine months that ended September 30, 2024, no warrants were exercised.

| (10) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of September 30, 2024, 32,283 warrants were exercised for a total consideration of $405,003. During the nine months that ended September 30, 2024, no warrants were exercised.

| (11) | Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.

| (12) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.

| (13) | Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.

| (14) | Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

| f. | Share-based compensation expense for employees and non-employees:

The Company recognized non-cash share-based compensation expenses for both employees and non-employees in the condensed consolidated statements of operations as follows (in thousands):

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Cost of revenues |  | $ | 12 |  |  | $ | 5 |
Research and development, net |  |  | 130 |  |  |  | 112 |
Sales and marketing |  |  | 309 |  |  |  | 270 |
General and administrative |  |  | 596 |  |  |  | 568 |
Total |  | $ | 1,047 |  |  | $ | 955 |

24

LIFEWARD LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 9: FINANCIAL INCOME, NET
The components of financial (expenses) income, net were as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Foreign currency transactions and other |  | $ | 38 |  |  | $ | 17 |  |  | $ | 1 |  |  | $ | 39 |
Interest income |  |  | 107 |  |  |  | 394 |  |  |  | 591 |  |  |  | 1,024 |
Bank commissions |  |  | (26 | ) |  |  | - |  |  |  | (97 | ) |  |  | (16 | )
|  | $ | 119 |  |  | $ | 411 |  |  | $ | 495 |  |  | $ | 1,047 |

NOTE 10: GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA
Summary information about geographic areas:
ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from selling systems and services. The following is a summary of revenues within geographic areas (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues based on customer’s location: |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 3,458 |  |  | $ | 2,497 |  |  | $ | 11,054 |  |  | $ | 4,298 |
Europe |  |  | 2,419 |  |  |  | 1,466 |  |  |  | 5,896 |  |  |  | 2,201 |
Asia-Pacific |  |  | 150 |  |  |  | 94 |  |  |  | 544 |  |  |  | 123 |
Rest of the world |  |  | 101 |  |  |  | 346 |  |  |  | 624 |  |  |  | 348 |
Total revenues |  | $ | 6,128 |  |  | $ | 4,403 |  |  | $ | 18,118 |  |  | $ | 6,970 |

|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Long-lived assets by geographic region (*): |  |  |  |  |  |
Israel |  | $ | 244 |  |  | $ | 529 |
United States |  |  | 1,777 |  |  |  | 2,404 |
Germany |  |  | 141 |  |  |  | 190 |
|  | $ | 2,162 |  |  | $ | 3,123 |

(*) | Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Major customer data as a percentage of total revenues: |  |  |  |  |  |
Customer A |  |  | 16.4 | % |  |  | - |
Customer B |  |  | * | ) |  |  | 15.9 | %

*) Less than 10%.
NOTE 11: SUBSEQUENT EVENTS
On November 4, 2024, the Company announced plans to streamline its U.S. operations by closing two facilities, following the integration of LCAI. The Company will focus its operations in Massachusetts, Israel, and Germany. Key functions located at the affected facilities will be integrated into the operations of the Marlborough, Massachusetts facility, and manufacturing of the AlterG Anti-Gravity Systems will be assumed by Cirtronics Corporation, a nationally recognized contract manufacturer specializing in the manufacture of precision medical devices and instrumentation.
25

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operation should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes included elsewhere in this quarterly report and with our audited consolidated financial statements included in our Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2024 and amended on April 29, 2024 (the “2023 Form 10-K”). In addition to historical condensed financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. For a discussion of factors that could cause or contribute to these differences, see “Special Note Regarding Forward-Looking Statements” above.
Overview
We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury (“SCI”) the ability to stand and walk again during everyday activities at home or in the community. In March 2023, we received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the ReWalk Personal Exoskeleton with stair and curb functionality which adds usage on stairs and curbs to the indication for use for the device in the U.S. The clearance permits U.S. customers to participate in more walking activities in real-world environments in their daily lives where stairs or curbs may have previously limited them when using the exoskeleton for its intended, FDA indicated uses. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years and consisting of over 18,000 stair steps was collected to demonstrate the safety and efficacy of this feature and support the FDA submission. In June 2024, we submitted a 510(k) premarket notification for ReWalk 7 Personal Exoskeleton device, a next-generation ReWalk model, and such 510(k) is pending FDA review.
We have sought to expand our product offerings beyond the SCI Products through internal development and distribution agreements. We have developed our ReStore Exo-Suit device (the “ReStore”), which we began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disabilities due to stroke. During the second quarter of 2020, we finalized and moved to implement two separate agreements to distribute additional product lines in the United States. We are the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through the Veterans Health Administration (“VHA”) hospitals.
On August 11, 2023, we made our first acquisition to supplement our internal growth when we acquired AlterG, a leading provider of anti-gravity system for use in physical and neurological rehabilitation. We paid a cash purchase price of approximately $19 million at closing and additional cash earnouts (initially estimated to be approximately $4 million in the aggregate) may be paid based upon a percentage of AlterG’s year-over-year revenue growth over the two years following the closing. The AlterG anti-gravity systems use patented, National Aeronautics and Space Administration-derived Differential Air Pressure (“DAP”) technology to reduce the effects of gravity and allow people to rehabilitate with finely calibrated support and reduced pain. AlterG anti-gravity systems are utilized in over 4,000 facilities globally in more than 40 countries. We will continue to evaluate other products for distribution or acquisition that can broaden our product offerings further to help individuals with neurological injury and disability.
26

We are in the research stage of ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke, and we are currently evaluating the reimbursement landscape and the potential clinical impact of this device. This product would be a complementary product to ReStore as it provides active assistance to the ankle during plantar flexion and dorsiflexion for gait and mobility improvement in the home environment, and it received Breakthrough Device Designation from the FDA in November 2021. Further investment in the development path of the ReBoot has been temporarily paused in 2023 pending further determination about the clinical and commercial opportunity of this device.
Our principal markets are primarily in the United States and Europe with some lesser sales to Asia, the Middle East and South America. We sell our products primarily directly in the United States, through a combination (depending on the product line) of direct sales and distributors in Germany, Canada, and Australia, and primarily through distributors in other markets. In our direct markets, we have established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the spinal cord injury community, and in markets where we do not sell direct to customers, our distributors maintain these relationships. We have offices in Marlborough, Massachusetts, Yokneam, Israel, Berlin, Germany, and Fremont, California from where we operate our business.
We have in the past generated and expect to generate in the future revenue from a combination of clinics and rehabilitation centers, commercial distributors, third-party payors (including private commercial and government payors), professional and college sports teams, and self-pay individuals. While a broad uniform policy of coverage and reimbursement by third-party commercial payors currently does not exist in the United States for exoskeleton technologies such as the ReWalk Personal Exoskeleton, we are pursuing various paths for coverage and reimbursement and support fundraising efforts by institutions and clinics, such as the VHA policy that was issued in December 2015 for the evaluation, training, and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans suffering from SCI across the United States.
We have also been pursuing updates with the Centers for Medicare and Medicaid Services (“CMS”), to clarify the Medicare coverage category (i.e., benefit category) applicable for personal exoskeletons. In 2022, the National Spinal Cord Injury Statistical Center (“NSCISC”) reported that Medicare and Medicaid are the primary payors for approximately 57% of the SCI population which are at least five years post their injury date, with Medicare representing a majority of this percentage. In July 2020, following a successful submission and hearing process, a Healthcare Common Procedure Coding System (“HCPCS”) code K1007 was issued (effective October 1, 2020) for lower-limb exoskeletons, including the ReWalk Personal Exoskeleton, which may be used for purposes of claim submission to Medicare, Medicaid, and other payors.
On November 1, 2023, CMS released the Calendar Year 2024 Home Health Prospective Payment System Final Rule, CMS-1780-F (“Final Rule”), which was adopted through the notice and comment rulemaking process. The Final Rule, which went into effect on January 1, 2024, includes a policy confirming that personal exoskeletons will be included in the Medicare brace benefit category. Medicare personal exoskeleton claims with dates of service on or after January 1, 2024 that are billed using HCPCS code K1007 will be assigned to the brace benefit category. CMS reimburses items classified under the brace benefit category using a lump sum payment methodology.
On April 11, 2024, CMS revised its April 2024 Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (“DMEPOS”) Fee Schedule to include a final lump-sum Medicare purchase fee schedule amount for personal exoskeletons (HCPCS code K1007) with an established rate of $91,032. The final payment determination was made by CMS by applying a “gap filling” process, which was used in light of CMS determining that the code describing the technology has no fee schedule pricing history and that lower extremity exoskeletons incorporate “revolutionary features” that cannot be described by or considered comparable to any other existing code or combination of codes. As part of gap-filling, CMS utilizes verifiable supplier or commercial pricing information and adjusts this pricing information according to a deflation and update factor methodology. In applying this formula to the K1007 code describing the ReWalk Personal Exoskeleton, CMS says that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers.
In Germany, we continue to make progress toward achieving coverage from the various government, private and worker’s compensation payors for our SCI Products. In September 2017, each of German insurer BARMER GEK (“BARMER”) and national social accident insurance provider Deutsche Gesetzliche Unfallversicherung (“DGUV”), indicated that they will provide coverage to users who meet certain inclusion and exclusion criteria. In February 2018, the head office of German Statutory Health Insurance (“SHI”) Spitzenverband (“GKV”) confirmed their decision to list the ReWalk Personal Exoskeleton system in the German Medical Device Directory. This decision means that ReWalk is listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis. During the year 2020 and 2021, we announced several new agreements with German SHIs, including TK and DAK Gesundheit, as well as the first German Private Health Insurer (“PHI”), which outline the process of obtaining our devices for eligible insured patients. We are also currently working with several additional SHIs on securing a formal operating contract that will establish the process of obtaining a ReWalk Personal Exoskeleton for their beneficiaries within their system. Additionally, to date, several private insurers in the United States and Europe are providing reimbursement for ReWalk in certain cases.
27

Third Quarter 2024 Business Highlights

| • | Lifeward initiated actions to further streamline its U.S. operations including closing two U.S. facilities to complete the integration of AlterG. The actions are expected to save the Company approximately $3 million in operating expenses and improve gross margins by approximately two percentage points when the full impact is achieved.

| • | Lifeward began selling the AlterG family of products through its German sales organization which the Company expects will result in revenue growth from a more focused sales effort and higher margins with little incremental investment by utilizing its existing sales and support infrastructure in Germany.

| • | Lifeward executed a successful launch of the AlterG NEO which was engineered with a new design to allow a lower price point to make the technology more accessible to a broader range of customers. Since the introduction of the NEO at the end of June, Lifeward has generated orders for approximately 40 units as the NEO is quickly becoming a growth driver for the AlterG product line.

| • | Lifeward completed its near-term plans to refresh its Board of Directors with the addition of Robert J. Marshall Jr. as a new director and chairman of the Audit Committee.

28

Results of Operations for the Three and Nine Months Ended September 30, 2024 and September 30, 2023
Our operating results for the three and nine months ended September 30, 2024, as compared to the same period in 2023, are presented below. The results set forth below are not necessarily indicative of the results to be expected in future periods.

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues |  |  | 6,128 |  |  |  | 4,403 |  |  | $ | 18,118 |  |  | $ | 6,970 |
Cost of revenues |  |  | 3,908 |  |  |  | 3,540 |  |  |  | 11,746 |  |  |  | 4,960 |
Gross profit |  |  | 2,220 |  |  |  | 863 |  |  |  | 6,372 |  |  |  | 2,010 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development, net |  |  | 998 |  |  |  | 1,262 |  |  |  | 3,494 |  |  |  | 2,830 |
Sales and marketing |  |  | 4,156 |  |  |  | 4,088 |  |  |  | 13,573 |  |  |  | 9,076 |
General and administrative |  |  | 240 |  |  |  | 3,455 |  |  |  | 3,424 |  |  |  | 7,579 |
Total operating expenses |  |  | 5,394 |  |  |  | 8,805 |  |  |  | 20,491 |  |  |  | 19,485 |
Operating loss |  |  | (3,174 | ) |  |  | (7,942 | ) |  |  | (14,119 | ) |  |  | (17,475 | )
Financial income, net |  |  | 119 |  |  |  | 411 |  |  |  | 495 |  |  |  | 1,047 |
Loss before income taxes |  |  | (3,055 | ) |  |  | (7,531 | ) |  |  | (13,624 | ) |  |  | (16,428 | )
Taxes on income |  |  | 29 |  |  |  | - |  |  |  | 40 |  |  |  | 66 |
Net loss |  | $ | (3,084 | ) |  | $ | (7,531 | ) |  | $ | (13,664 | ) |  | $ | (16,494 | )
Net loss per ordinary share, basic and diluted |  | $ | (0.35 | ) |  | $ | (0.88 | ) |  | $ | (1.58 | ) |  | $ | (1.94 | )
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (1) |  |  | 8,756,882 |  |  |  | 8,542,630 |  |  |  | 8,652,085 |  |  |  | 8,501,397 |

29

Three and Nine Months Ended September 30, 2024 Compared to Three and Nine Months Ended September 30, 2023
Revenue
Our revenue for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Revenues |  | $ | 6,128 |  |  | $ | 4,403 |  |  | $ | 18,118 |  |  | $ | 6,970 |

Revenues are derived from the sale of SCI Products, AlterG anti-gravity systems, ReStore systems, and units of the Distributed Product. We also generate revenue from the sale of extended warranties and the provision of repair services for the products that we sell.
Revenues increased by $1.7 million, or 39%, for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily driven by an increase in ReWalk system sold from the expansion of access through Medicare coverage, stronger sales performance in Germany and an increase in AlterG sales compared to the three months ended September 30, 2023, which had a partial quarter contribution following the closing of the acquisition in August 2023.
Revenues increased by $11.1 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily driven by an increase in ReWalk system sold from the expansion of access through Medicare coverage, stronger sales performance in Germany and due to the revenue contribution of AlterG following the closing of the acquisition in August 2023.
In the future, we expect our growth to be driven by sales of our ReWalk Personal device through expansion of coverage and reimbursement by commercial and government third-party payors, as well as sales of AlterG anti-gravity systems and units of the Distributed Product.
Gross Profit
Our gross profit for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Gross profit |  | $ | 2,220 |  |  | $ | 863 |  |  | $ | 6,372 |  |  | $ | 2,010 |

Gross profit was 36.2% of revenue for the three months ended September 30, 2024, compared to 19.6% for the three months ended September 30, 2023. Gross profit included amortization of intangible assets and the step-up value of inventory related to the acquisition of AlterG of $0.4 million and $1.1 million for the three months ended September 30, 2024 and 2023, respectively. Excluding the impact of the acquisition related charges, gross profit as a percentage of revenue was 42.5% for the three months ended September 30, 2024, down 2.6 percentage points from the three months ended September 30, 2023. This decrease was a result of an unfavorable absorption of production and overhead costs from lower production volume.
Gross profit was 35.2% of revenue for the nine months ended September 30, 2024, compared to 28.8% for the nine months ended September 30, 2023. Gross profit included amortization of intangible assets and the step-up value of inventory related to the acquisition of AlterG of $1.2 million and $1.1 million for the nine months ended September 30, 2024 and 2023, respectively. Excluding the impact of the acquisition related charges, gross profit as a percentage of revenue was 41.7% for the nine months ended September 30, 2024, down 3.2 percentage points from the nine months ended September 30, 2023. This decline was a result of a low volume of AlterG product sales in the first quarter, which resulted in adverse absorption of production and overhead costs, partially offset by volume leverage from a higher volume of ReWalk product sales.
We expect gross profit and gross profit as a percentage of revenue will increase in the future as we increase our revenue volumes and realize operating efficiencies associated with greater scale which will reduce the cost of revenue as a percentage of revenue. Additionally, we expect gross profit as a percentage of revenue to increase as a result of the closure of our Fremont manufacturing facility at the end of 2024 and the move of production to a contract manufacturer. Improvements may be partially offset by increased material costs, shipping costs, and costs of service.
Research and Development Expenses, net
Our research and development expenses, net, for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Research and development, net |  | $ | 998 |  |  | $ | 1,262 |  |  | $ | 3,494 |  |  | $ | 2,830 |

Research and development expenses were $0.9 million for the three months ended September 30, 2024, a decrease of $0.3 million, or 20.1%, compared to the three months ended September 30, 2023. The decrease is primarily attributable to the completion of the development program for the ReWalk 7.
Research and development expenses were $3.5 million for the nine months ended September 30, 2024, an increase of $0.7 million or 23.5%, compared to the nine months ended September 30, 2023. This increase is primarily due to the acquisition of AlterG, which contributed partially following the acquisition's close in August 2023, and included investments in new product development projects. This was partially offset by lower subcontracting and consulting expenses following the completion of the ReWalk 7 development program.
We intend to focus our research and development resources primarily on supporting our current products, advancing the ongoing product development activities for our AlterG Anti-Gravity systems, and preparing for the next stages following our recent FDA 510(k) submission for clearance of the ReWalk 7 next-generation exoskeleton model.
30

Sales and Marketing Expenses
Our sales and marketing expenses for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Sales and marketing |  | $ | 4,156 |  |  | $ | 4,088 |  |  | $ | 13,573 |  |  | $ | 9,076 |

Sales and marketing expenses were $4.2 million for the three months ended September 30, 2024, an increase of $0.1 million, or 2%, compared to the three months ended September 30, 2023. These expenses included amortization of intangible assets from the AlterG acquisition, amounting to $0.4 million in the third quarter of 2024 and $0.2 million in the third quarter of 2023. The remaining decrease of $0.1 million is due to a reduction in consulting expenses related to the CMS reimbursement process, partially offset by a limited consolidation of AlterG following the acquisition in August 2023.
Sales and marketing expenses totaled $13.6 million for the nine months ended September 30, 2024, reflecting an increase of $4.5 million, or 49.5%, compared to the same period in 2023. These expenses included amortization of intangible assets related to the AlterG acquisition, amounting to $1.2 million for the nine months ended September 30, 2024, compared to $0.2 million in the same period in 2023. The remaining $3.6 million increase is mainly due to higher personnel-related expenses from increased headcount following the AlterG acquisition and additional spending on promotional activities.
Our sales and marketing efforts are expected to focus on driving growth in our commercial product portfolio, expanding the reimbursement coverage by commercial payors of our ReWalk Personal Exoskeleton device, and expanding the commercial and clinical capabilities of the Lifeward organization.
General and Administrative Expenses
Our general and administrative expenses for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
General and administrative |  | $ | 240 |  |  | $ | 3,455 |  |  | $ | 3,424 |  |  | $ | 7,579 |

General and administrative expenses were $0.3 million for the three months ended September 30, 2024, a decrease of $3.2 million, or 93%, compared to the same period in 2023. These expenses for the three months ended September 30, 2024, included $0.1 million in amortization of intangible assets related to the AlterG acquisition and $2.0 million in income from an adjustment to remeasure the earnout liability from the AlterG acquisition. The remaining $1.2 million decrease was primarily due to a reduction of $1.3 million in M&A-related expenses, partially offset by higher personnel-related costs.
General and administrative expenses were $3.4 million for the nine months ended September 30, 2024, a decrease of $4.2 million, or 54.8%, compared to the same period in 2023. These expenses for the nine months ended September 30, 2024, included $0.2 million in amortization of intangible assets from the AlterG acquisition, $2.5 million in other income from the remeasurement of the earnout liability related to the AlterG acquisition, and an additional $0.5 million in other income from post-closing statement adjustments associated with the acquisition. The remaining $1.4 million decrease is primarily due to a reduction of $2.3 million in M&A-related expenses, partially offset by the full nine-month contribution of AlterG expenses and higher professional services costs.
Financial Income, Net
Our financial income, net, for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Financial income, net |  | $ | 119 |  |  | $ | 411 |  |  | $ | 495 |  |  | $ | 1,047 |

Financial income, net, decreased by $0.3 million, or 71%, for the three months ended September 30, 2024, compared to the three months ended September 30, 2023. This decrease was primarily due to yield on a lower cash balance resulting from the funding of the growth of Lifeward over the past year.
Financial income, net, decreased by $0.6 million, or 52.7%, for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. This decrease was primarily due to yield on a lower cash balance resulting from the acquisition of AlterG and funding of the growth of Lifeward over the past year.
31

Income Taxes
Our income tax for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands):

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Taxes on income |  | $ | 29 |  |  | $ | - |  |  | $ | 40 |  |  | $ | 66 |

Income taxes increased by $29 thousand, for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, mainly due to deferred taxes and timing differences in our subsidiaries.
Income taxes decreased by $26 thousand, or 39.4%, for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, mainly due to the utilization of net operation losses forward arising from the acquisition of AlterG.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed financial statements requires us to make estimates, judgments and assumptions that can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, judgments, and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our condensed financial statements and related disclosures. See Note 2 to our audited consolidated financial statements included in our 2023 Form 10-K for a description of the significant accounting policies that we used to prepare our consolidated financial statements.
There have been no material changes to our critical accounting policies or our critical judgments from the information provided in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies” of our 2023 Form 10-K, except for the updates provided in Note 3 of our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” of this quarterly report.
Recent Accounting Pronouncements
See Note 3 to our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” of this quarterly report for information regarding new accounting pronouncements.
Liquidity and Capital Resources
Sources of Liquidity and Outlook
Since inception, we have funded our operations primarily through the sale of certain of our equity securities and convertible notes to investors in private placements, the sale of our ordinary shares in public offerings and the incurrence of bank debt.
During the nine months ended September 30, 2024, we incurred a consolidated net loss of $13.7 million and have an accumulated deficit in the total amount of $249.5 million. Our cash and cash equivalents as of September 30, 2024, totaled $10.7 million and our negative operating cash flow for the nine months ended September 30, 2024, was $17.7 million. We believe that we have sufficient funds to support our operations for more than 12 months following the issuance date of our condensed consolidated unaudited financial statements for the nine months ended September 30, 2024.
In November 2024, we began streamlining our U.S. operations, including closing two U.S. facilities to complete the integration following the acquisition of AlterG. As a result of the organizational changes, we reduced our total headcount by greater than 35% since the closing of the AlterG acquisition. Key functions located at the affected facilities will be integrated into the operations of the Marlborough, Massachusetts facility, and manufacturing of the AlterG Anti-Gravity Systems will be assumed by Cirtronics Corporation, a nationally recognized contract manufacturer specializing in the manufacture of precision medical devices and instrumentation. We estimate that such consolidation will save the Company approximately $3 million in operating expenses and improve gross margins when the full impact is achieved, which we expect to contribute to our goal of reducing costs and achieving profitability.
We expect to incur future net losses and our transition to profitability is dependent upon, among other things, the successful development and commercialization of our products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenues adequate to support our cost structure. If the Company does not achieve a level of revenues adequate to support its cost structure, it will implement cost reduction measures. These plans may include restructuring efforts and additional cost reductions if needed. Until we achieve profitability or generate positive cash flows, we will continue to need to raise additional cash from time to time.
We intend to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, we may seek additional capital through arrangements with strategic partners or from other sources and we will continue to address our cost structure. Notwithstanding, there can be no assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
32

Our anticipated primary uses of cash are (i) sales, marketing and reimbursement expenses related to market development activities for our ReWalk Personal device and AlterG anti-gravity system, broadening third-party payor and CMS coverage for our ReWalk Personal device and commercializing our new product lines added through distribution agreements; (ii) development of future generation designs for our spinal cord injury device, new AlterG products utilizing DAP technology, and our lightweight exo-suit technology for potential home personal health utilization for multiple indications; (iii) routine product updates; (iv) potential acquisitions of businesses, such as our recent acquisition of AlterG,; and (v) general corporate purposes, including working capital needs. Our future cash requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities, the timing and extent of our spending on research and development efforts, the attractiveness of potential acquisition candidates, and international expansion. If our current estimates of revenue, expenses or capital or liquidity requirements change or are inaccurate, we may seek to sell additional equity or debt securities or arrange for bank debt financing. There can be no assurance that we will be able to raise such funds at all or on acceptable terms.
Equity Raises
Use of Form S-3
Beginning with the filing of our Form 10-K on February 17, 2017, we were subject to limitations under the applicable rules of Form S-3, which constrained our ability to secure capital with respect to public offerings pursuant to our effective Form S-3. These rules limit the size of primary securities offerings conducted by issuers with a public float of less than $75 million to no more than one-third of their public float in any 12-month period. At the time of filing our 2023 Form 10-K, on February 27, 2024, we were subject to these limitations because our public float did not reach at least $75 million in the 60 days preceding the filing of our 2023 Form 10-K. We will continue to be subject to these limitations for the remainder of the 2024 fiscal year and until the earlier of such time as our public float reaches at least $75 million or when we file our next annual report for the year ended December 31, 2024, at which time we will be required to re-test our status under these rules. If our public float is below $75 million as of the filing of our next annual report on Form 10-K, or at the time we file a new Form S-3, we will continue to be subject to these limitations, until the date that our public float again reaches $75 million. These limitations do not apply to secondary offerings for the resale of our ordinary shares or other securities by selling shareholders or to the issuance of ordinary shares upon conversion by holders of convertible securities, such as warrants. We have registered up to $100 million of ordinary shares warrants and/or debt securities and certain other outstanding securities with registration rights on our registration statement on Form S-3, which was declared effective by the SEC in May 2022.
Share Repurchase Program
On June 2, 2022, our board of directors approved a share repurchase program to repurchase up to $8.0 million of our ordinary shares. On July 21, 2022, we received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, our board of directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.
As of September 30, 2024, pursuant to the share repurchase program, we had repurchased a total of 574,658 of our outstanding ordinary shares at a total cost of $3.5 million.
33

Cash Flows for the nine Months Ended September 30, 2024 and 2023 (in thousands):

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Net cash used in operating activities |  | $ | (17,749 | ) |  | $ | (16,183 | )
Net cash used in investing activities |  |  | - |  |  |  | (18,070 | )
Net cash used in financing activities |  |  | - |  |  |  | (992 | )
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash |  |  | (29 | ) |  |  | (24 | )
Net cash flow |  | $ | (17,778 | ) |  | $ | (35,269 | )

Net Cash used in Operating Activities
Net cash used in operating activities increased by $1.6 million, or 9.7%, for the nine months ended September 30, 2024 primarily due to increase in trade receivables from the timing of Medicare payments for initial claims to be paid and increased inventory purchases for the establishment of safety stock of ReWalk systems as a result of the continuing conflict in Israel and in preparation for the future new product introduction of the ReWalk 7.
Net Cash used in Operating Activities
Net cash used in investing activities decreased by $18.1 million, primarily due to the acquisition of AlterG that took place in 2023.
Net Cash used in Financing Activities
Net cash used in financing activities decreased by $1 million, or 100%, for the nine months ended September 30, 2024. The decrease is due to the repurchase of our ordinary shares under our repurchase program, which expired on August 9, 2023.
Obligations and Contractual Commitments
Set forth below is a summary of our contractual obligations as of September 30, 2024.

|  | Payments due by period (in dollars, in thousands) |
Contractual obligations |  | Total |  |  | Less than 1 year |  |  | 1-3 years |
Purchase obligations (1) |  | $ | 5,929 |  |  | $ | 5,929 |  |  | $ | - |
Collaboration Agreement and License Agreement obligations (2) |  |  | 35 |  |  |  | 35 |  |  |  | - |
Operating lease obligations (3) |  |  | 1,024 |  |  |  | 974 |  |  |  | 50 |
Earnout liability (4) |  |  | 792 |  |  |  | - |  |  |  | 792 |
Total |  | $ | 7,780 |  |  | $ | 6,938 |  |  | $ | 842 |

(1) | We depend on one contract manufacturer, Sanmina Corporation, for both the SCI products and the ReStore Products. We place our manufacturing orders with Sanmina pursuant to purchase orders or by providing forecasts for future requirements. The AlterG Anti-Gravity systems are currently produced in Fremont, California by us and following the upcoming closure of our Fremont manufacturing facility at the end of 2024, we will move production to a contract manufacturer. Purchase orders are executed with suppliers based on our sales forecast.
(2) | Under the Collaboration Agreement, we were required to pay in quarterly installments the funding of our joint research collaboration with Harvard, subject to a minimum funding commitment under applicable circumstances. Our License Agreement with Harvard consists of patent reimbursement expenses payments and a license upfront fee payment. There are also several milestone payments contingent upon the achievement of certain product development and commercialization milestones and royalty payments on net sales from certain patents licensed to Harvard. All product development milestones contemplated by the License Agreement have been met as of September 30, 2024; however, there are still outstanding commercialization milestones under the License Agreement that depend on us reaching certain sales amounts, some or all of which may not occur. Our Collaboration Agreement with Harvard was concluded on March 31, 2022.
(3) | Our operating leases consist of leases for our facilities in the United States and Israel and motor vehicles.
(4) | Earnout payments based on AlterG’s revenue growth during the trailing twelve-month periods a year following closing of the transaction.

We calculated the payments due under our operating lease obligation for our Israeli office that are to be paid in NIS at a rate of exchange of NIS 3.71: $1.00, and the payments due under our operating lease obligation for our German subsidiary that are to be paid in euros at a rate of exchange of €1.00: $1.12, both of which were the applicable exchange rates as of September 30, 2024.
34

Off-Balance Sheet Arrangements
We had no off-balance sheet arrangements or guarantees of third-party obligations as of September 30, 2024.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to our market risk during the third quarter of 2024. For a discussion of our exposure to market risk, please see Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our 2023 Form 10-K.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure.
As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon, and as of the date of, this evaluation, the Chief Executive Officer and the Principal Financial Officer concluded that our disclosure controls and procedures were effective such that the information required to be disclosed by us in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
During the quarter ended September 30, 2024 there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
35

PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
There have been no material changes to our legal proceedings as described in “Part I, Item 3. Legal Proceedings” of our 2023 Form 10-K, except as described in Note 7 in our condensed consolidated financial statements included in “Part I, Item 1” of this quarterly report.
ITEM 1A. RISK FACTORS
Except as disclosed in our Quarterly Report on Form 10-Q for the period ended March 31, 2024, and our Quarterly Report on Form 10-Q for the period ended June 30, 2024, there have been no material changes to our risk factors from those disclosed in “Part I, Item 1A. Risk Factors” of our 2023 Form 10-K.
36

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Not applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408(a) of Regulation S-K).
37

ITEM 6. EXHIBIT INDEX

Exhibit Number |  | Description
3.1** |  | Sixth Amended and Restated Articles of Association of the Company.
31.1** |  | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.
31.2** |  | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.
32.1* |  | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2* |  | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS |  | XBRL Instance Document
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
104 |  | Cover Page Interactive Data File – formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.

__________________________

* | Furnished herewith.
** | Filed herewith
^ | Portions of this exhibit (indicated by asterisks) have been omitted under rules of the SEC permitting the confidential treatment of select information.

38

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Lifeward Ltd.
Date: November 12, 2024 | By: | /s/ Larry Jasinski
|  | Larry Jasinski
|  | Chief Executive Officer (Principal Executive Officer)
Date: November 12, 2024 | By: | /s/ Michael Lawless
|  | Michael Lawless
|  | Chief Financial Officer
|  | (Principal Financial Officer)

39